According to sources, Lupin has entered into negotiations with Astellas and Shionogi to acquire their off-patent drug brands, as reported The Economic Times Wednesday.
The sources noted that each company's portfolio could fetch $100 million in a sale, noting that the acquisition could expand Lupin's offerings in Japan, where the company amassed 10 percent of its revenue last fiscal year.
Lupin previously bolstered its Japanese businesses by acquiring a majority stake in stake in its Japanese partner Kyowa in 2007 and purchasing specialty injectables manufacturer I'rom Pharmaceutical in 2011.
Meanwhile, some Japanese companies have recently sought to offload old drugs and use the proceeds to fund R&D.
"Japan is a less understood fertile market," an expert remarked, adding "acquiring brands is identified as the best way to make a foray. Those who start from scratch either fail or have a long runway to reach critical mass."
To read more NewsPoints articles, click here.